Cancer Cell Signalling
Herausgegeben von Harvey, Amanda
Cancer Cell Signalling
Herausgegeben von Harvey, Amanda
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
A focused, accessible introduction to this key aspect of cancerbiology. It covers the individual cell signalling pathways that areknown to be involved in cancer development, and, most important,includes the cross- interactions between the pathways together withthe current therapeutic approaches. This is a'must-have' for advanced undergraduate and postgraduatestudents studying and researching within the field of cancerbiology.
Andere Kunden interessierten sich auch für
- Vinagolu K. RajasekharCancer Stem Cells223,99 €
- Molecular Biology of Cancer 2e124,99 €
- Stem Cell Therapeutics for Can186,99 €
- The Molecular Biology of Cancer205,99 €
- Novartis Foundation SymposiumSignalling Networks in Cell Shape and Motility218,99 €
- Ribosome-Inactivating Proteins168,99 €
- When Cells Die II224,99 €
-
-
-
A focused, accessible introduction to this key aspect of cancerbiology. It covers the individual cell signalling pathways that areknown to be involved in cancer development, and, most important,includes the cross- interactions between the pathways together withthe current therapeutic approaches. This is a'must-have' for advanced undergraduate and postgraduatestudents studying and researching within the field of cancerbiology.
Produktdetails
- Produktdetails
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 228
- Erscheinungstermin: 11. November 2013
- Englisch
- Abmessung: 241mm x 168mm x 15mm
- Gewicht: 452g
- ISBN-13: 9781119967576
- ISBN-10: 1119967570
- Artikelnr.: 39380142
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 228
- Erscheinungstermin: 11. November 2013
- Englisch
- Abmessung: 241mm x 168mm x 15mm
- Gewicht: 452g
- ISBN-13: 9781119967576
- ISBN-10: 1119967570
- Artikelnr.: 39380142
Dr Amanda Harvey, Brunel Institute for Cancer Genetics and Pharmacogenomics, Brunel University, Kingston Lane, Middlesex, UK.
List of contributors ix Acknowledgements xi Introduction xiii About the
companion website xvi 1 Epidermal growth factor receptor family 1 Amanda
Harvey 1.1 ErbB receptors and their structure 1 1.2 ErbB ligands 2 1.3
Downstream signalling molecules and events 5 1.4 Signalling regulation 8
1.5 Dysregulation of signalling in cancer 10 1.6 Therapeutic opportunities
13 References 17 2 Insulin and the insulin-like growth factor (IGF) family
25 Maria Thorpe, Erald Shehu and Amanda Harvey 2.1 Receptors 25 2.2 Ligands
28 2.3 Downstream signalling molecules and events 30 2.4 Dysregulation of
signalling in cancer 32 2.5 Therapeutic opportunities 34 References 37 3
Transforming growth factor-ß receptor signalling 45 Gudrun Stenbeck 3.1
TGFß receptors 45 3.2 Ligands 48 3.3 Downstream signalling molecules and
events 49 3.4 Signalling regulation 53 3.5 Dysregulation of signalling in
cancer 56 3.6 Therapeutic opportunities 58 References 60 4 Wnt signalling
67 David Tree 4.1 Introduction and overview 67 4.2 The ligands: Wnt
proteins, their modification and secretion 69 4.3 The receptors: Frizzleds
and LRPs, multiple receptors and combinations 70 4.4 Regulation of
signalling 71 4.5 When good signalling goes bad: Wnt signalling in diseases
79 4.6 Taming the beast: drugs and small molecule inhibitors targeting Wnt
signalling 80 4.7 Conclusion and perspectives 81 References 82 5 Mammalian
target of rapamycin (mTOR) signalling 93 Maria Thorpe and Emmanouil
Karteris 5.1 Discovery of mTOR 93 5.2 mTOR complexes 94 5.3 mTOR
dysregulation in disease 99 5.4 Therapeutic opportunities 104 References
107 6 c-Met receptor signalling 115 Stephen Hiscox 6.1 Historical context -
identification of the MET gene 115 6.2 c-Met expression, activation and
signal transduction 119 6.3 Physiological roles of c-Met 121 6.4 c-Met and
cancer 123 6.5 c-Met as a potential therapeutic target in malignancy 128
6.6 Summary 130 References 130 7 Vascular endothelial growth factor and its
receptor family 139 Katarzyna Leszczynska, Christopher Hillyar and Ester M.
Hammond 7.1 VEGF receptors 139 7.2 Ligands 140 7.3 Downstream signalling
molecules and events 143 7.4 Signalling regulation 150 7.5 Dysregulation of
signalling in cancer 152 7.6 Therapeutic opportunities 153 References 158 8
Progesterone receptor signalling in breast cancer models 171 Andrea R.
Daniel, Todd P. Knutson, Christy R. Hagan and Carol A. Lange 8.1
Progesterone receptor function 172 8.2 Model systems: context for studying
PR biochemistry 174 8.3 Progesterone receptor signalling 175 8.4 Regulation
of signalling 176 8.5 Tissue specific PR actions (breast versus
reproductive tract) 181 8.6 Progesterone receptor and cancer 183 8.7
Summary 183 References 184 9 Signalling cross-talk 193 Amanda Harvey 9.1
Introduction 193 9.2 Examples of cross-talk 195 9.3 Convergence of
signalling at downstream foci 197 9.4 Common signalling components 198 9.5
Compensatory signalling 202 9.6 Summary 203 References 203 Index 207
companion website xvi 1 Epidermal growth factor receptor family 1 Amanda
Harvey 1.1 ErbB receptors and their structure 1 1.2 ErbB ligands 2 1.3
Downstream signalling molecules and events 5 1.4 Signalling regulation 8
1.5 Dysregulation of signalling in cancer 10 1.6 Therapeutic opportunities
13 References 17 2 Insulin and the insulin-like growth factor (IGF) family
25 Maria Thorpe, Erald Shehu and Amanda Harvey 2.1 Receptors 25 2.2 Ligands
28 2.3 Downstream signalling molecules and events 30 2.4 Dysregulation of
signalling in cancer 32 2.5 Therapeutic opportunities 34 References 37 3
Transforming growth factor-ß receptor signalling 45 Gudrun Stenbeck 3.1
TGFß receptors 45 3.2 Ligands 48 3.3 Downstream signalling molecules and
events 49 3.4 Signalling regulation 53 3.5 Dysregulation of signalling in
cancer 56 3.6 Therapeutic opportunities 58 References 60 4 Wnt signalling
67 David Tree 4.1 Introduction and overview 67 4.2 The ligands: Wnt
proteins, their modification and secretion 69 4.3 The receptors: Frizzleds
and LRPs, multiple receptors and combinations 70 4.4 Regulation of
signalling 71 4.5 When good signalling goes bad: Wnt signalling in diseases
79 4.6 Taming the beast: drugs and small molecule inhibitors targeting Wnt
signalling 80 4.7 Conclusion and perspectives 81 References 82 5 Mammalian
target of rapamycin (mTOR) signalling 93 Maria Thorpe and Emmanouil
Karteris 5.1 Discovery of mTOR 93 5.2 mTOR complexes 94 5.3 mTOR
dysregulation in disease 99 5.4 Therapeutic opportunities 104 References
107 6 c-Met receptor signalling 115 Stephen Hiscox 6.1 Historical context -
identification of the MET gene 115 6.2 c-Met expression, activation and
signal transduction 119 6.3 Physiological roles of c-Met 121 6.4 c-Met and
cancer 123 6.5 c-Met as a potential therapeutic target in malignancy 128
6.6 Summary 130 References 130 7 Vascular endothelial growth factor and its
receptor family 139 Katarzyna Leszczynska, Christopher Hillyar and Ester M.
Hammond 7.1 VEGF receptors 139 7.2 Ligands 140 7.3 Downstream signalling
molecules and events 143 7.4 Signalling regulation 150 7.5 Dysregulation of
signalling in cancer 152 7.6 Therapeutic opportunities 153 References 158 8
Progesterone receptor signalling in breast cancer models 171 Andrea R.
Daniel, Todd P. Knutson, Christy R. Hagan and Carol A. Lange 8.1
Progesterone receptor function 172 8.2 Model systems: context for studying
PR biochemistry 174 8.3 Progesterone receptor signalling 175 8.4 Regulation
of signalling 176 8.5 Tissue specific PR actions (breast versus
reproductive tract) 181 8.6 Progesterone receptor and cancer 183 8.7
Summary 183 References 184 9 Signalling cross-talk 193 Amanda Harvey 9.1
Introduction 193 9.2 Examples of cross-talk 195 9.3 Convergence of
signalling at downstream foci 197 9.4 Common signalling components 198 9.5
Compensatory signalling 202 9.6 Summary 203 References 203 Index 207
List of contributors ix Acknowledgements xi Introduction xiii About the
companion website xvi 1 Epidermal growth factor receptor family 1 Amanda
Harvey 1.1 ErbB receptors and their structure 1 1.2 ErbB ligands 2 1.3
Downstream signalling molecules and events 5 1.4 Signalling regulation 8
1.5 Dysregulation of signalling in cancer 10 1.6 Therapeutic opportunities
13 References 17 2 Insulin and the insulin-like growth factor (IGF) family
25 Maria Thorpe, Erald Shehu and Amanda Harvey 2.1 Receptors 25 2.2 Ligands
28 2.3 Downstream signalling molecules and events 30 2.4 Dysregulation of
signalling in cancer 32 2.5 Therapeutic opportunities 34 References 37 3
Transforming growth factor-ß receptor signalling 45 Gudrun Stenbeck 3.1
TGFß receptors 45 3.2 Ligands 48 3.3 Downstream signalling molecules and
events 49 3.4 Signalling regulation 53 3.5 Dysregulation of signalling in
cancer 56 3.6 Therapeutic opportunities 58 References 60 4 Wnt signalling
67 David Tree 4.1 Introduction and overview 67 4.2 The ligands: Wnt
proteins, their modification and secretion 69 4.3 The receptors: Frizzleds
and LRPs, multiple receptors and combinations 70 4.4 Regulation of
signalling 71 4.5 When good signalling goes bad: Wnt signalling in diseases
79 4.6 Taming the beast: drugs and small molecule inhibitors targeting Wnt
signalling 80 4.7 Conclusion and perspectives 81 References 82 5 Mammalian
target of rapamycin (mTOR) signalling 93 Maria Thorpe and Emmanouil
Karteris 5.1 Discovery of mTOR 93 5.2 mTOR complexes 94 5.3 mTOR
dysregulation in disease 99 5.4 Therapeutic opportunities 104 References
107 6 c-Met receptor signalling 115 Stephen Hiscox 6.1 Historical context -
identification of the MET gene 115 6.2 c-Met expression, activation and
signal transduction 119 6.3 Physiological roles of c-Met 121 6.4 c-Met and
cancer 123 6.5 c-Met as a potential therapeutic target in malignancy 128
6.6 Summary 130 References 130 7 Vascular endothelial growth factor and its
receptor family 139 Katarzyna Leszczynska, Christopher Hillyar and Ester M.
Hammond 7.1 VEGF receptors 139 7.2 Ligands 140 7.3 Downstream signalling
molecules and events 143 7.4 Signalling regulation 150 7.5 Dysregulation of
signalling in cancer 152 7.6 Therapeutic opportunities 153 References 158 8
Progesterone receptor signalling in breast cancer models 171 Andrea R.
Daniel, Todd P. Knutson, Christy R. Hagan and Carol A. Lange 8.1
Progesterone receptor function 172 8.2 Model systems: context for studying
PR biochemistry 174 8.3 Progesterone receptor signalling 175 8.4 Regulation
of signalling 176 8.5 Tissue specific PR actions (breast versus
reproductive tract) 181 8.6 Progesterone receptor and cancer 183 8.7
Summary 183 References 184 9 Signalling cross-talk 193 Amanda Harvey 9.1
Introduction 193 9.2 Examples of cross-talk 195 9.3 Convergence of
signalling at downstream foci 197 9.4 Common signalling components 198 9.5
Compensatory signalling 202 9.6 Summary 203 References 203 Index 207
companion website xvi 1 Epidermal growth factor receptor family 1 Amanda
Harvey 1.1 ErbB receptors and their structure 1 1.2 ErbB ligands 2 1.3
Downstream signalling molecules and events 5 1.4 Signalling regulation 8
1.5 Dysregulation of signalling in cancer 10 1.6 Therapeutic opportunities
13 References 17 2 Insulin and the insulin-like growth factor (IGF) family
25 Maria Thorpe, Erald Shehu and Amanda Harvey 2.1 Receptors 25 2.2 Ligands
28 2.3 Downstream signalling molecules and events 30 2.4 Dysregulation of
signalling in cancer 32 2.5 Therapeutic opportunities 34 References 37 3
Transforming growth factor-ß receptor signalling 45 Gudrun Stenbeck 3.1
TGFß receptors 45 3.2 Ligands 48 3.3 Downstream signalling molecules and
events 49 3.4 Signalling regulation 53 3.5 Dysregulation of signalling in
cancer 56 3.6 Therapeutic opportunities 58 References 60 4 Wnt signalling
67 David Tree 4.1 Introduction and overview 67 4.2 The ligands: Wnt
proteins, their modification and secretion 69 4.3 The receptors: Frizzleds
and LRPs, multiple receptors and combinations 70 4.4 Regulation of
signalling 71 4.5 When good signalling goes bad: Wnt signalling in diseases
79 4.6 Taming the beast: drugs and small molecule inhibitors targeting Wnt
signalling 80 4.7 Conclusion and perspectives 81 References 82 5 Mammalian
target of rapamycin (mTOR) signalling 93 Maria Thorpe and Emmanouil
Karteris 5.1 Discovery of mTOR 93 5.2 mTOR complexes 94 5.3 mTOR
dysregulation in disease 99 5.4 Therapeutic opportunities 104 References
107 6 c-Met receptor signalling 115 Stephen Hiscox 6.1 Historical context -
identification of the MET gene 115 6.2 c-Met expression, activation and
signal transduction 119 6.3 Physiological roles of c-Met 121 6.4 c-Met and
cancer 123 6.5 c-Met as a potential therapeutic target in malignancy 128
6.6 Summary 130 References 130 7 Vascular endothelial growth factor and its
receptor family 139 Katarzyna Leszczynska, Christopher Hillyar and Ester M.
Hammond 7.1 VEGF receptors 139 7.2 Ligands 140 7.3 Downstream signalling
molecules and events 143 7.4 Signalling regulation 150 7.5 Dysregulation of
signalling in cancer 152 7.6 Therapeutic opportunities 153 References 158 8
Progesterone receptor signalling in breast cancer models 171 Andrea R.
Daniel, Todd P. Knutson, Christy R. Hagan and Carol A. Lange 8.1
Progesterone receptor function 172 8.2 Model systems: context for studying
PR biochemistry 174 8.3 Progesterone receptor signalling 175 8.4 Regulation
of signalling 176 8.5 Tissue specific PR actions (breast versus
reproductive tract) 181 8.6 Progesterone receptor and cancer 183 8.7
Summary 183 References 184 9 Signalling cross-talk 193 Amanda Harvey 9.1
Introduction 193 9.2 Examples of cross-talk 195 9.3 Convergence of
signalling at downstream foci 197 9.4 Common signalling components 198 9.5
Compensatory signalling 202 9.6 Summary 203 References 203 Index 207